Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN) -- Ignore unavailable to you. Want to Upgrade?

To: kech who wrote (137)	4/27/1998 9:13:00 PM
From: Shlepper	Read Replies (1) \| Respond to of 233

Tom, I'll try to hang around after his spiel and talk to him over the coffee and cookies. Although i'm always concerned of the competition, I'm more concerned when Cytolex hits the market. Then the fun will begin... Shep

To: kech who wrote (137)	5/7/1998 10:16:00 PM
From: Shlepper	Read Replies (1) \| Respond to of 233

Tom, One of my best friends met with Zasloff today at the NIH, and then listened to the lecture (Paul Ehrlich). I had revised my schedule (picking up my daughter from college, etc.) so that I could attend, but I was so worn out and under the weather, that I didn't make it. Wish I had - the talk from Zasloff was well-received and all of the big shots were there. The lecture ended around 3:00. Interestingly enough, the volume and price of magainin moved up after the lecture. Wonder if some biotech analysts were in attendance. My take is that Zasloff's science and approach have gained acceptance in the community. Credibility goes a long way in gaining funds for trials and teaming partners. Feeling good - but sorry about not asking the questions you had. Maybe can be asked at the stockholders meeting? Good Luck, Shep